Lakefront Biotherapeutics (LKFT) Depreciation & Amortization (CF) (2016 - 2018)

Lakefront Biotherapeutics (LKFT) has 3 years of Depreciation & Amortization (CF) data on file, last reported at $1.1 million in Q3 2018.

• Depreciation & Amortization (CF) for Q3 2018 came in at $1.1 million, up 5.0% year-over-year; the trailing twelve-month figure through Jun 2019 was $1.1 million (down 64.96% YoY), and the FY2020 annual result was $22.3 million, up 61.66% from the prior year.
• Depreciation & Amortization (CF) was little changed at $1.1 million in Q3 2018 per LKFT's latest filing, from $1.1 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.1 million in Q3 2018 and troughed at $832774.2 in Q1 2016.
• A 3-year average of $1.0 million and a median of $1.0 million in 2017 frame the typical range for Depreciation & Amortization (CF).
• On a YoY basis, Depreciation & Amortization (CF) climbed as much as 13.55% in 2018 and fell as far as 5.0% in 2018.
• A 3-year view of Depreciation & Amortization (CF) shows it stood at $925367.6 in 2016, then increased by 10.7% to $1.0 million in 2017, then advanced by 10.93% to $1.1 million in 2018.
• Business Quant data shows LKFT's Depreciation & Amortization (CF) at $1.1 million in Q3 2018, $1.1 million in Q2 2018, and $1.0 million in Q4 2017.